Hans Schambye
Galecto reaps $64M to bring lead drug across IPF finish line, while making moves in NASH and beyond
Back in 2018, Hans Schambye raised $90 million to kick off a late-stage trial that could put Galecto Biotech’s lead drug on the final …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.